Saturday, March 2, 2024

CATEGORY

Novartis

The First and Only Pharmaceutical Food Allergy Therapy Xolair Gains New FDA Approval

As it nears the end of its patent life, Roche and Novartis' Xolair for food allergy is making significant strides by gaining groundbreaking new...

Therapy for Gastroenteropancreatic Neuroendocrine Tumors Novartis’ Lutathera® Cuts Risk by 72% in First-Line Treatment

The Phase III NETTER-2 trial has marked a significant advancement in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Novartis, a leader in radioligand therapy...

In Chronic Myeloid Leukemia Trial, Scemblix Exhibits Higher MMR Rates

Novartis has recently announced the groundbreaking results of its ASC4FIRST Phase III trial, which marks a significant advancement in the treatment of chronic myeloid...

In Phase III Chronic Myeloid Leukemia Trial, Novartis’ Scemblix® Outperforms Standard TKIs

Novartis has announced positive results from the ASC4FIRST Phase III trial, comparing Scemblix® (asciminib) with other tyrosine kinase inhibitors (TKIs) in newly diagnosed patients...

New State-of-the-Art Radioligand Therapy Facility in Indianapolis by Novartis

Novartis, a global leader in pharmaceuticals, has achieved a significant milestone with the FDA approval of its second US Radioligand Therapy (RLT) manufacturing facility,...

Novartis Boosts Mid-Term Sales Growth Outlook

Novartis presented its 'pure-play' innovative medicines strategy and outlined plans for its Research and Development pipeline during a dedicated event in London. This strategic...

Remibrutinib: Early Symptom Improvement in Chronic Spontaneous Urticaria – Novartis Data

In pivotal Phase III trials, remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, demonstrated a significant reduction in urticaria activity compared to placebo. The trials,...

Novartis’ Cosentyx Gains FDA Approval: A New Hope for Severe Skin Disease Treatment

The U.S. FDA has given its approval to Novartis' Cosentyx (secukinumab) for the treatment of moderate to severe hidradenitis suppurativa (HS), a painful skin...

Novartis Has Completed The Spin-Off of Sandoz, Its Generics and Biosimilars Division

Novartis successfully carried out the Sandoz Spin-off, marking the conclusion of its strategic transformation into prominent pharmaceuticals. This separation was executed through a dividend-in-kind...

Novartis Has Successfully Concluded The Sale of Its Ophthalmology Assets Related to The “Front of The Eye.”

Novartis has completed the divestment of its ophthalmology assets related to the "front of the eye" to Bausch + Lomb, a global eye health...

Latest news

Sticky Image